CHRO insider buying and SEC filings, explained
Chromocell Therapeutics Corp · CIK 1919246
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$1.0M
Insiders who bought
1
Sold (not marked 10b5-1)
$321K
Planned sales (10b5-1)
$166K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 2, 2026 | Planned (10b5-1) | Peter Greenleaf (Director) sold 797 shares at $21.17 ($17K), marked as a 10b5-1 plan trade. Holdings down 3% to 23,087 shares. | SEC filing Filed Oct 6, 2026, 5:54 PM ET |
| Oct 2, 2026 | Planned (10b5-1) | Ezra M Friedberg (Director) sold 558 shares at $20.72 ($12K), marked as a 10b5-1 plan trade. Holdings down 1% to 80,484 shares. | SEC filing Filed Oct 6, 2026, 5:53 PM ET |
| Oct 2, 2026 | Planned (10b5-1) | Matthew Pauls (Director) sold 786 shares at $21.00 ($17K), marked as a 10b5-1 plan trade. Holdings down 5% to 13,578 shares. | SEC filing Filed Oct 6, 2026, 5:53 PM ET |
| Jul 2, 2026 | Planned (10b5-1) | Ezra M Friedberg (Director) sold 558 shares at about $26.09 ($15K), marked as a 10b5-1 plan trade. Holdings down 1% to 81,042 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Matthew Pauls (Director) sold 786 shares at about $26.16 ($21K), marked as a 10b5-1 plan trade. Holdings down 5% to 14,364 shares. | SEC filing Filed Jul 7, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Peter Greenleaf (Director) sold 797 shares at about $26.14 ($21K), marked as a 10b5-1 plan trade. Holdings down 3% to 23,884 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Ezra M Friedberg (Director) sold 283 shares at about $27.29 ($8K), marked as a 10b5-1 plan trade. Holdings down <1% to 81,600 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 11, 2026 | Purchase (code P) | Todd C Davis (Director) bought 35,948 shares at about $27.81 ($1.0M), reported as a purchase (code P). Holdings up 90% to 75,834 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 22, 2026 | Sale | Knuettel Francis II (CFO) sold 1,500 shares indirectly (by trust) at about $26.84 ($40K). Holdings by trust down 12% to 11,316 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Richard Malamut (Director) sold 590 shares at about $20.91 ($12K), marked as a 10b5-1 plan trade. Holdings down 2% to 27,422 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Ezra M Friedberg (Director) sold 558 shares at about $20.91 ($12K), marked as a 10b5-1 plan trade. Holdings down 1% to 82,027 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Matthew Pauls (Director) sold 786 shares at about $20.92 ($16K), marked as a 10b5-1 plan trade. Holdings down 5% to 15,150 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Peter Greenleaf (Director) sold 797 shares at about $20.92 ($17K), marked as a 10b5-1 plan trade. Holdings down 3% to 24,681 shares. | SEC filing Filed Apr 6, 2026 |
| Nov 25, 2025 | Sale | Ezra M Friedberg (Director) sold 10,000 shares indirectly (by entity) at about $28.03 ($280K). Holdings by entity down 25% to 30,000 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CHRO in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.